A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

Abstract Background Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel...

Full description

Bibliographic Details
Main Authors: Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, Toniva Boone, Angel A. Rodriguez, Poly A. Niravath, Jorge G. Darcourt, Jane L. Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia G. Kaklamani, Jenny C. Chang
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Breast Cancer Research
Subjects:
Neoadjuvant
HER2
Ado-trastuzumab emtansine
T-DM1
Lapatinib
Nab-paclitaxel
Online Access:http://link.springer.com/article/10.1186/s13058-019-1186-0

Internet

http://link.springer.com/article/10.1186/s13058-019-1186-0

Similar Items